Levalbuterol (Xopenex) Respiratory Pharmacology Guide

Short-acting beta2 agonists stimulate beta2-adrenergic receptors on bronchial smooth muscle, rapidly increasing intracellular cAMP and producing bronchodilation. Levalbuterol belongs to the same SABA class as albuterol, but contains only the R-enantiomer rather than a racemic mixture.

Levalbuterol stimulates beta2-adrenergic receptors on bronchial smooth muscle. These receptors couple to Gs proteins, activate adenylyl cyclase, increase intracellular cyclic AMP, activate protein kinase A, reduce calcium-mediated myosin phosphorylation, and relax airway smooth muscle. Beta2 stimulation in skeletal muscle contributes to tremor, and beta2-mediated intracellular potassium shifting can cause transient hypokalemia.

Levalbuterol is a rescue bronchodilator, not a controller medication. It may relieve acute bronchospasm, but frequent use suggests poor asthma or COPD control and should prompt reassessment of controller therapy such as inhaled corticosteroids or long-acting bronchodilators.

Levalbuterol begins working within approximately 5 to 15 minutes, peaks around 30 to 90 minutes, and usually lasts 4 to 6 hours. Nebulized solution may have bronchodilator activity lasting up to 8 hours in some labeling. Levalbuterol is eliminated primarily through the kidneys as parent drug and sulfate conjugates, with an approximate half-life of 3 to 4 hours.

Levalbuterol HFA is commonly dosed as 2 inhalations of 45 mcg each every 4 to 6 hours as needed. Nebulized levalbuterol is commonly dosed at 0.63 mg three times daily in adults and adolescents, with lower pediatric starting doses such as 0.31 mg three times daily for children 6 to 11 years. Concentrated nebulizer solution must be diluted with normal saline according to product instructions.

Levalbuterol should not be overused. Increasing need for rescue medication may indicate deteriorating asthma or COPD control. Serious warnings include paradoxical bronchospasm, cardiovascular stimulation, tachyarrhythmias, QT-related concerns, hypersensitivity reactions, and clinically significant hypokalemia in susceptible patients.

Nonselective beta blockers may blunt levalbuterol bronchodilation and can worsen bronchospasm. Loop or thiazide diuretics may increase hypokalemia risk. Digoxin levels may be affected by beta agonists, and MAO inhibitors or tricyclic antidepressants may potentiate cardiovascular effects. Other sympathomimetics, stimulants, theophylline, caffeine, or decongestants may increase tachycardia and palpitations.

Monitor symptom relief, peak flow or FEV1 response when available, work of breathing, wheezing, respiratory rate, heart rate, tremor, palpitations, potassium risk, rescue inhaler frequency, inhaler technique, nebulizer technique, and evidence of worsening disease control.

These are the answer choices, mechanisms, or medication classes most commonly confused with this medication on RT school and NBRC-style exams.

• Albuterol
• Formoterol
• Ipratropium
• Tiotropium

• Acute asthma exacerbation requiring rapid bronchodilation
• COPD exacerbation combined with ipratropium
• Mechanically ventilated patient receiving aerosol therapy
• Patient intolerant of racemic albuterol
• Frequent rescue inhaler use indicating uncontrolled asthma

• Use levalbuterol for rapid relief of acute bronchospasm.
• Do not use levalbuterol as long-term asthma controller monotherapy.
• Frequent rescue use should trigger reassessment of asthma or COPD control.
• Consider levalbuterol when a patient reports intolerance to racemic albuterol, but recognize evidence for fewer side effects is inconsistent.
• Combine short-acting beta agonist therapy with ipratropium during moderate-to-severe COPD exacerbations when appropriate.
• Monitor heart rate, tremor, potassium risk, and response to therapy after administration.

• Assuming levalbuterol always causes less tachycardia than albuterol.
• Confusing levalbuterol with a LABA such as formoterol.
• Forgetting that levalbuterol is rescue therapy, not controller therapy.
• Confusing beta2 agonist adverse effects with anticholinergic adverse effects.
• Selecting levalbuterol alone for persistent asthma without anti-inflammatory therapy.
• Forgetting that levalbuterol is the R-enantiomer of albuterol.

• Use levalbuterol as a rescue bronchodilator, not as your daily controller medication.
• Seek medical advice if you need levalbuterol more often than prescribed or if it stops providing usual relief.
• Shake and prime the inhaler according to product instructions before use.
• Use slow inhalation, coordinated actuation, and a breath hold when using the MDI.
• Clean the inhaler mouthpiece regularly to prevent blockage.
• Expect possible tremor, nervousness, faster heartbeat, headache, or dizziness.
• Report chest pain, severe palpitations, worsening breathing, rash, or swelling immediately.
• Do not double doses or exceed the prescribed frequency.

• Assess pre- and post-bronchodilator response when clinically appropriate.
• Review inhaler technique and spacer use for patients with poor coordination.
• Use device-specific dosing because nebulizer and MDI nominal doses are not directly equivalent.
• Monitor heart rate and tremor after repeated treatments.
• Consider SABA plus ipratropium in moderate-to-severe COPD exacerbation protocols.
• In ventilated patients, optimize aerosol device placement and circuit technique to improve deposition.

• For HFA inhaler use: shake, exhale fully, seal lips, actuate while inhaling slowly, hold breath for about 10 seconds, then exhale.
• Wait about 1 minute between inhalations when multiple puffs are prescribed.
• Prime the HFA inhaler when new or unused for several days according to product instructions.
• For nebulizer use: place the ordered unit dose into the nebulizer cup and breathe calmly until mist stops.
• Dilute concentrate formulations with normal saline as directed before nebulization.
• Clean nebulizer equipment after use according to manufacturer and institutional instructions.

• Identify levalbuterol as a SABA.
• Compare levalbuterol versus racemic albuterol.
• Recognize beta2 agonist adverse effects.
• Distinguish rescue therapy from controller therapy.
• Identify beta blocker and hypokalemia interactions.
• Apply nebulizer and MDI administration technique.
• Recognize SABA overuse as a sign of poor control.